<DOC>
	<DOC>NCT01419665</DOC>
	<brief_summary>The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.</brief_summary>
	<brief_title>GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient with previously untreated advanced stage, CD20positive FL Patient with ECOG performance status 0, 1 or 2. Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a Patient who has previously received any prior therapy for lymphoma Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal). Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Biosimilar</keyword>
	<keyword>GP13-301</keyword>
	<keyword>rituximab</keyword>
	<keyword>Antibodies</keyword>
	<keyword>CD20</keyword>
</DOC>